Pharmaceutical firm Radionetics Oncology has named Dr. Nishan de Silva as CEO and a director of the company's board. De Silva most recently was with AFYX Therapeutics.
De Silva led a phase 2 clinical trial program for a sponsor-conducted study in oral lichen planus while at AFYX Therapeutics. Before heading AFYX Therapeutics, de Silva served as president and chief operating officer of Poseida Therapeutics, a gene therapy and gene editing therapeutics-focused company.
Radionetics Oncology is focused on the discovery and development of radiotherapeutics for the treatment of a wide range of oncology indications. The company has added eight new members to its management team since it launched in October 2021.
